| Kristine Noelle Pavlovic, FNP | |
|
272 N Main St, Unit 101, Cambridge, VT 05444 | |
| (802) 644-5114 | |
| (802) 888-6075 |
| Full Name | Kristine Noelle Pavlovic |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 272 N Main St, Cambridge, Vermont |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831885169 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 101.0136022 (Vermont) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 101.0136022 (Vermont) | Primary |
| Entity Name | Lamoille Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124436332 PECOS PAC ID: 4789586942 Enrollment ID: O20040216000714 |
News Archive
The World Health Organization (WHO) and Sanofi – one of the world's leading pharmaceutical companies – have signed a new agreement for donations of medicines to sustain specific efforts to eliminate neglected tropical diseases (NTDs).
Cintas Corporation, the leader in secure document management, today announced that nominations for its 2010 Excellence in Healthcare Information Management Award are now open. The award will recognize one leading healthcare facility that has gone above and beyond to implement secure document strategies to protect its patients' private information and remain compliant with government standards.
METTLER TOLEDO has announced a new online seminar, titled Flow Chemistry Development and Scale-up. Each presentation includes examples of how simple PAT tools have become integrated into continuous flow chemistry to expedite process development. Each presenter will share a series of technical case studies.
Researchers at San Francisco-based Brain Plasticity, Inc. (BPI) have begun a multi-center study to evaluate the effects of a computerized, brain-plasticity-based program designed to address the cognitive issues associated with schizophrenia.
Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristine Noelle Pavlovic, FNP Po Box 749, Morrisville, VT 05661-0749 Ph: (802) 851-8619 | Kristine Noelle Pavlovic, FNP 272 N Main St, Unit 101, Cambridge, VT 05444 Ph: (802) 644-5114 |
News Archive
The World Health Organization (WHO) and Sanofi – one of the world's leading pharmaceutical companies – have signed a new agreement for donations of medicines to sustain specific efforts to eliminate neglected tropical diseases (NTDs).
Cintas Corporation, the leader in secure document management, today announced that nominations for its 2010 Excellence in Healthcare Information Management Award are now open. The award will recognize one leading healthcare facility that has gone above and beyond to implement secure document strategies to protect its patients' private information and remain compliant with government standards.
METTLER TOLEDO has announced a new online seminar, titled Flow Chemistry Development and Scale-up. Each presentation includes examples of how simple PAT tools have become integrated into continuous flow chemistry to expedite process development. Each presenter will share a series of technical case studies.
Researchers at San Francisco-based Brain Plasticity, Inc. (BPI) have begun a multi-center study to evaluate the effects of a computerized, brain-plasticity-based program designed to address the cognitive issues associated with schizophrenia.
Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).
› Verified 1 days ago